Login to Your Account



Clinic Roundup


Tuesday, October 9, 2012
• Isconova AB, of Uppsala, Sweden, said its partner, the Jenner Institute at Oxford University, received approval from the UK's Medicines and Healthcare products Regulatory Agency to start a Phase I study of a malaria vaccine candidate containing Isconova's adjuvant Matrix-M.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription